You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Treatment Augmentation in Major Depressive Disorder: Expert Insights on Real-World Considerations

  • Authors: Joseph F. Goldberg, MD; Brooke A. Kempf, PMHNP; Michael E. Thase, MD
  • CME / ABIM MOC / CE Released: 11/10/2023
  • Valid for credit through: 11/10/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians, nurse practitioners, physician assistants, pharmacists, family practitioners, and other clinicians who treat patients with major depressive disorder (MDD).

The goal of this activity is for learners to be better able to use measurement-based care to assess symptoms and response to treatment for MDD as well as to communicate with patients to engage them in shared decision-making regarding treatment options.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data for therapeutic agents used for augmentation of antidepressant treatment
  • Have greater competence related to the
    • Use of validated tools to assess response to antidepressant treatment
  • Demonstrate greater confidence in their ability to
    • Engage patients in shared decision-making regarding augmentation strategies for MDD treatment


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Joseph F. Goldberg, MD

    Clinical Professor of Psychiatry
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Disclosures

    Joseph F. Goldberg, MD, has the following relevant financial relationships: 
    Consultant or advisor for: BioXcel Therapeutics; Neumora; Neurelis, Inc.; Otsuka Pharmaceutical Co., Ltd.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.
    Speaker or member of speakers bureau for: AbbVie Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Intra-Cellular Therapies, Inc.

Faculty

  • Brooke A. Kempf, PMHNP

    PMHNP Hamilton Center CMHC
    Terre Haute, Indiana
    Adjunct Faculty, IUPUI
    Indianapolis, Indiana

    Disclosures

    Brooke A. Kempf, PMHNP, has the following relevant financial relationships: 
    Consultant or advisor for: Alkermes, Inc.; Intra-Cellular Therapies, Inc.; Otsuka Pharmaceutical Co., Ltd.; Takeda; Teva Pharmaceutical Industries Ltd.
    Speaker or member of speakers bureau for: AbbVie Inc. (former); Alkermes, Inc.; Axsome Therapeutics, Inc.; Biogen; Intra-Cellular Therapies, Inc.; Janssen; Otsuka Pharmaceutical Co., Ltd.; Sage Therapeutics, Inc.; Takeda; Teva Pharmaceutical Industries Ltd.

  • Michael E. Thase, MD

    Professor, Department of Psychiatry
    Mood and Anxiety Disorders Treatment and Research Program
    University of Pennsylvania Perelman School of Medicine
    Corporal Michael J. Crescenz Veterans Affairs Medical Center
    Philadelphia, Pennsylvania

    Disclosures

    Michael E. Thase, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Autobahn Therapeutics; Axsome Therapeutics, Inc.; Clexio Biosciences; Gerson Lehman; GH Therapeutics; H. Lundbeck A/S; Janssen Pharmaceuticals; Johnson & Johnson Services, Inc.; Luye Pharma Group; Merck & Co., Inc.; Object Pharma; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sage Therapeutics, Inc.; Seelos Therapeutics; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.
    Research funding from: ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Intra-Cellular Therapies, Inc.; Janssen Pharmaceuticals; Myriad; Otsuka Pharmaceutical Co., Ltd.; Takeda Pharmaceuticals North America, Inc.

Editor

  • Lisette Arnaud-Hevi, PhD

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Lisette Arnaud-Hevi, PhD, has no relevant financial relationships. 

Compliance Reviewer/Nurse Planner

  • Maria Morales, MSN, RN, CLNC

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Maria Morales, MSN, RN, CLNC, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Treatment Augmentation in Major Depressive Disorder: Expert Insights on Real-World Considerations

Authors: Joseph F. Goldberg, MD; Brooke A. Kempf, PMHNP; Michael E. Thase, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/10/2023

Valid for credit through: 11/10/2024, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print